Abstract | Antimicrobial treatment failure threatens our ability to control infections. In addition to antimicrobial resistance, treatment failures are increasingly understood to derive from cells that survive drug treatment without selection of genetically heritable mutations. Parasitic protozoa, such as Plasmodium species that cause malaria, Toxoplasma gondii and kinetoplastid protozoa, including Trypanosoma cruzi and Leishmania spp., cause millions of deaths globally. These organisms can evolve drug resistance and they also exhibit phenotypic diversity, including the formation of quiescent or dormant forms that contribute to the establishment of long-term infections that are refractory to drug treatment, which we refer to as 'persister-like cells'. In this Review, we discuss protozoan persister-like cells that have been linked to persistent infections and discuss their impact on therapeutic outcomes following drug treatment.
Treatment failure of antimicrobial agents is a serious global health threat 1 . Drug resistance emerges from mutations in the microbial genome that enable micro organisms to survive in the presence of drugs 2 and that are propagated in a genetically stable manner. Microorganisms can also be refractory to drugs with out the selection of genetic mutations. In 1944, Irish physician Joseph Bigger 3 noted that in a population of Staphylococcus aureus a small proportion of cells were refractory to penicillin; cells within this subpopu lation are termed 'persisters' . The formation of non replicating but viable cells is common among bacteria [4] [5] [6] [7] and a fundamental and ancient evolutionary adaptive mechanism 8 , whereby a small subpopulation of cells spontaneously enter dormancy or quiescence, terms we use interchangeably in this Review, given that different authors have used the terms arbitrarily in their studies describing cells that are non replicating or replicating very slowly with associated metabolic alterations such as diminished DNA synthesis, and widespread down regulation of protein translation when compared with replicative cells. These cells are less vulnerable to a range of transient environmental stresses, including immuno logical attack and drug treatment 8 . Once those condi tions pass, this population can return to a proliferative state and recolonize the environment. Although the dormant state enables bacteria to survive stress, it is not necessarily triggered by stress; instead dormancy occurs spontaneously [4] [5] [6] [7] , and recent preliminary data point to new approaches to identify and isolate low numbers of spontaneously arising Mycobacterium smegmatis persisters 9 (that is, a subpopulation of cells is prepared for the sudden onset of stress).
Eukaryotic cells also enter quiescent/dormant states that affect drug susceptibility, and drug tolerant persister like cell types have been described for both fungi 10 and cancer cells 11 . Protozoan parasites are eukaryotes that cause millions of deaths each year. Treatment failure of antiparasitic drugs is of concern, and drug resistance mechanisms in parasitic protozoa are increasingly understood and have recently been reviewed elsewhere 12 . Protozoa use various mechanisms to establish per sistent infections, including mechanisms to manipulate and avoid host immunity 13, 14 . In this Review, we focus on parasite stages that are capable of entering a quies cent/dormant state and relate this phenomenon to drug treatment failure. In bacteria, metabolic divergence from proliferative cells is a hallmark of quiescence 15 , and a number of pathways implicated in metabolic adapta tion have been identified; for example, toxin-antitoxin systems 16 and stress response pathways [4] [5] [6] [7] . Several studies have shown that parasitic proto zoa can generate various forms during their life cycle that have been linked to persistence. In particular, the hypnozoite stages of Plasmodium vivax and related Plasmodium species have been shown to cause persistent infections and they have been linked to drug treatment failure. Moreover, it has been shown that Plasmodium falciparum parasites can enter a transient growth arrested state as ring forms in erythrocytes, during which time they are refractory to artemisinin based drugs.
Persisters
A subpopulation of slowgrowing or growth-arrested cells that have a decreased susceptibility to killing by normally effective cytotoxic agents. Persisters survive treatment with drugs because of their altered metabolism during a temporary state of quiescence and are genetically identical to other, drugsusceptible cells in the population. Persisters may arise stochastically or in response to environmental cues such as nutrient starvation.
In Toxoplasma gondii, the switch between the rapi dly proliferative tachyzoite form and the slow replicating tissue cyst bound bradyzoite form underpins chronic infections that are refractory to treatment. In addi tion, it was recently shown that Trypanosoma cruzi can form dormant, transiently non proliferating amastigote forms 17 . Finally, evidence indicates Leishmania spp. form semiquiescent amastigotes 18 . These protozoan parasites exhibit a loss of sensitivity to drugs that kill more rapidly proliferating cells because of phenotypic differences related to slow or arrested growth.
In this Review, we describe these forms as 'persister like cells' . We describe the current knowledge of the observed forms and their possible role in persistent infections and treatment failure and we outline possi ble treatment options. Key features of bacterial persister cells and their protozoan persister like counterparts described in this Review are compared in 
Plasmodium species
More than 200 million people are infected with malaria causing parasites of the genus Plasmodium, which cause the death of approximately half a million individuals annually 19 . The parasites have a complex life cycle involving both an Anopheles mosquito vector and a vertebrate host. Infection begins when sporozoite forms of human infectious Plasmodium species are injected by female Anopheles mosquitoes during a blood meal. Sporozoites rapidly invade liver cells, where the para sites undergo a proliferative stage, including substan tial nuclear division without cell division to produce a schizont. Subsequent cytokinesis results in the forma tion of multiple merozoites that are released into the bloodstream and invade erythrocytes (developing into the erythrocytic stages). During infection with P. vivax in humans and Plasmodium cynomolgi in monkeys, a small number of liver stage parasites enter a different developmental stage, termed the 'hypnozoite' , which can remain dormant for many months to years before entering the proliferative stage through schizogony. Within the erythrocyte, differentiation to a ring form then a feeding trophozoite that consumes haemoglobin precedes a further round of schizogony and the release of multiple merozoites. Depending on the species, this asexual erythrocyte cycle takes either 2 days or 3 days. Some schizonts, instead of producing typical merozoites that proceed through further rounds of asexual repro duction, produce cells that on reinfection of the next erythrocyte will form either male or female gameto cytes. These non proliferating gametocytes recombine www.nature.com/nrmicro when they enter a mosquito during a blood meal, creat ing a zygote that further matures into a motile ookinete, which can migrate out of the mosquito midgut, where it matures into an oocyst. Within the oocyst, sporo zoite forms develop before bursting from the oocyst, and these move to the salivary gland of the mosquito, from where the sporozoites are injected into the human host during the next blood meal of the mosquito 19 . Sporozoites are a non replicative form of the parasites. Persistent forms, outlined below, that affect therapeu tic outcomes are known for some Plasmo dium species that dwell in the liver and also during the erythrocytic stages. Other quiescent stages, for example the gameto cytes, have also been considered as an important target for novel chemotherapy as they are refractory to most drugs used against replicative bloodstream forms 20 .
The hypnozoite. Hypnozoites have been indicated in persistent infections with P. vivax, and they have been linked to drug treatment failure for some forms of malaria, particularly those caused by P. vivax and Plasmodium ovale in humans and the monkey malaria parasite P. cynomolgi. Hypnozoites can persist for weeks, months or even years before activation by unknown cues promotes schizogony 21, 22 . These growth arrested parasites arise spontaneously from a small number of the invading sporozoites, while most commence schizogony almost immediately (Fig. 1a) . Relapse arising from differen tiation of hypnozoites into proliferative liver stage schizonts that in turn create merozoites may be more rapid in tropical strains, whereas in more temperate cli mates, hypnozoite activation can occur 1 year or more after infection, to coincide with warm weather and high mosquito prevalence 23 . Morphologically, hypnozoites are uninucleate, non growing stages first described in liver biopsy samples from P. vivax infected chimpan zees and P. cynomolgi infected rhesus monkeys 24, 25 . Hypnozoite driven relapse is a major impediment to malaria elimination globally.
The biology of hypnozoites is poorly understood, given the difficulties of studying a very rare parasite inside host liver cells and the lack of appropriate rodent models. However, several studies probing P. vivax or P. cynomolgi biology following sporozoite invasion of either immortalized hepatoma cells or primary hepato cytes have revealed key insights into hypnozoite biology. For example, histone acetyltransferase inhibitors can activate hypnozoites 26 and the assessment of liver stage active drugs has been possible 27, 28 . Transcriptome analy sis of P. cynomolgi 29 and P. vivax 27 has revealed stage specific gene expression, and comparison of P. cynomolgi liver stages at 9-10 days after infection 30 with those at 6-7 days 29 showed that schizonts express many genes and that most metabolic pathways are active. By contrast, hypnozoites exhibit a marked decrease in the expression of genes for most biochemi cal pathways between day 6 and day 9, which indicates progressive entry into a quiescent state. However, simi larly to other known persister cell types, quiescence does not involve the complete downregulation of metabolic pathways. Several pathways remain active, including 45, 47 . The top panel shows Giemsa-stained parasites (purple) inside erythrocytes. The lower panel provides a representation of the upper panel in which key structures visible in light microscopy are visible. The diameter of the erythrocyte is 6 µm. Part a adapted with permission from reF.
those involved in protection against oxidative and other stresses, protein export, ATP maintenance and pro tein post translational modifications, including those involved in genome structure (for example, histone methylation and acetylation) 30 , which suggests that epigenetic changes may contribute to the regulation of gene expression and heterochromatin structure in hypnozoites.
Fluorescent reporters have allowed the enrichment of P. cynomolgi liver stages 31 . A miniaturized culture system of P. vivax infected primary human hepatocytes has offered new models to study liver stage infection 28, 32 and can be used for high content imaging based assays to identify new hypnozoiticidal drugs. Immunodeficient mice, engrafted with human hepatocytes, have allowed the study of P. vivax liver stages 33 , including the eluci dation of the hypnozoite maturation process, which allowed the testing of putative hypnozoiticidal drugs and the identification of upregulated in infectious sporozoites protein 4 (UIS4) as a liver specific marker for hypnozoites 33, 34 However, transcripts that are found only in hypnozoites and not other liver stages were not identified 31 . Therapeutic options for hypnozoites are very limited. Most erythrocytic stage active drugs are inactive against hypnozoites. This may be due to the absence of pathways such as haem degradation, which is targeted by chlo roquine, and the absence of pathways that are targeted by artemisinins. However, primaquine and its newly approved analogue tafenoquine are 8aminoquinolines with proven efficacy against hypnozoites (and also liver stage schizonts). These drugs are most effective when given in combination with chloroquine or quinine, which have some synergistic effect with primaquine 35, 36 . Primaquine is metabolized in the liver by the host cytochrome P450 2D6 into short lived reactive meta bolites. Different cytochrome P450 2D6 variants have been associated with reduced primaquine metabolism in the host and diminished primaquine efficacy 37, 38 . However, reduced cytochrome P450 2D6 activity is not associated with decreased tafenoquine efficacy 39, 40 even though tafenoquine metabolites have been shown to eliminate liver stage parasites in rodents 41 . This sug gests that unmetabolized tafenoquine or metabolites created by different metabolic routes may have acti vity against liver stages for this drug. Unfortunately, 8aminoquinoline metabolites can also cause serious side effects in glucose 6phosphate dehydrogenase (G6PD)deficient patients, in whom haemolytic anaemia may occur. An estimated 35% of people at risk of malaria caused by P. vivax are therefore not eligible for primaquine treatment either due to G6PD deficiency or due to impaired cytochrome P450 2D6 activity 42 . G6PD diagnostic tests will be used in conjunction with tafenoquine following its approval in the United States and Australia for human use to exclude enzyme deficient patients from treatment. New hypnozoiticidal drugs without G6PD liabil ties are urgently needed, and the recent breakthroughs in hypnozoite models described above might expedite the discovery of novel avenues to target hypnozoites and thus increase treatment success.
Recently discovered phosphatidylinositol 4kinase (PI4K) inhibitors 43 generated some excitement given their potency against liver stages of P. cynomolgi in vitro, yet treatment with such inhibitors failed to prevent relapses in rhesus monkeys challenged with sporozoites of P. cynomolgi 44 . Despite this result, important insights into hypnozoite biology emerged from these studies; crucially, it was shown that hypnozoites mature by day 4-5 after infection of hepatocytes into PI4K inhibitor refractory forms, whereas exposure to these inhibitors during early infection eliminates liver stage infection.
Artemisinin-induced dormant ring stages. In addition to hypnozoites, recent evidence has pointed to another type of transiently growth arrested form of P. falciparum that profoundly affects malaria therapy. Exposure of ring stages of P. falciparum to artemisinin derivatives (for example, dihydroartemisinin (DHA)) can induce a cell cycle arrest that is time and dose dependent. These non replicating ring stage parasites persist in erythro cytes for days to weeks before they resume normal asex ual growth 45, 46 . This artemisinin induced dormancy is characterized phenotypically by small parasites showing condensed nuclei (Fig. 1b) . Whether such forms can also arise spontaneously is not known.
Artemisinin induced dormancy has been confirmed in P. falciparum from lines that are refractory to the drug and also lines that are susceptible to the drug 45, 47 , which suggests the involvement of an adaptive stress response in the formation of this dormant ring form 48 . Dormant ring stages are physiologically distinct from normal ring stage forms as shown by upregulation of fatty acid and pyruvate metabolism 49 and maintenance of mitochon drial membrane potential 50 . Although artemisinin based drugs induce dormancy during ring stage development, other current antimalarials, including quinolines, anti folates and atovaquone, do not seem to affect ring forms. However, the antifolate pyrimethamine can induce ring stage arrest and dormant ring forms in the asexual cycle but not in the cycle where the drug is applied but rather in the following cycle. Hence, parasites initially exposed to pyrimethamine develop into mature schizonts, some of which produce merozoites that invade new erythro cytes and only then arrest development as dormant ring stages 48 . These observations explain the results of studies with pyrimethamine 51, 52 that found recrudescent para sites following drug exposure. This suggests the possibil ity of adaptive fitness advantages of dormancy (starting at different parts of the life cycle) for parasite survival against a range of stresses rather than a specific response to artemisinins. Additional drug or nutritional stress ors can arrest development of intraerythrocytic stages of P. falciparum. These include isoleucine starvation 53 , atovaquone exposure 54 , and difluoromethylornithine induced depletion of polyamines 55 . However, these conditions block trophozoite development and thus differ from artemisinin induced cell cycle arrest in ring stage parasites. Artemisinins (which are activated by cleavage of their endoperoxide bridge) alkylate many proteins in the parasite 56, 57 , which leads to protein mis folding and ubiquitinylation and subsequent induction of the unfolded protein response involving protein 
Sporozoite
in Plasmodium parasites, a form forming in mosquitoes, where it migrates to salivary glands and is injected during a blood meal. it migrates to the liver and invades hepatocytes. in Toxoplasma, an infectious form found in oocysts, the product of the sexual phase, which is shed into the environment and contaminates food and water, leading to transmission. The sporozoite persists in a semidormant state within the oocysts, surviving for many months in the environment.
Schizont
A multinucleated form of the Plasmodium parasite that forms through multiple nuclear divisions preceding cellular division to release merozoite forms. Can occur either in erythrocytes or before the erythrocytic cycle in hepatocytes.
Merozoites
Forms of Plasmodium parasites that emerge from liver cells after differentiation and invade red cells, where the asexual life cycle progression ultimately creates many more merozoites, which burst from infected red cells and invade new ones.
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degradation by the proteasome. However, treatment with artemi sinins also diminishes proteasome activity 58 , and parasite death seems to be linked to the accumu lation of damaged protein 58 . Inhibition of translation by the chemo therapeutic agent cyclophosphamide was shown to antagonize the antimalarial activity of DHA 58 . Growth arrested ring stages induced by artemisinin are likely to have diminished protein synthesis, which would explain why the drug loses activity against such forms.
Parasites isolated from patients in whom artemisinin treatment failed in South East Asia were characterized by low clearance rates from blood 59 . However, these parasites did not show alterations in artemisinin sensi tivity in classic in vitro potency tests conducted over 72 h (reF. 60 ). The reasons for this became clear in sub sequent studies into understanding the nature of arte misinin treatment failure. In vitro selection of resistance in increasing doses of artemisinin 61 revealed that these parasites also failed to yield discriminatory susceptibility to the drug in classic assays but did show an enhanced rate of dormant ring form formation. Mutated alleles of the gene Pfk13, encoding kelch protein 13 (Pfk13), were associated with parasites from artemisinin treatment failures in field studies as well as the in vitro selected line 62 . In each case, classic in vitro sensitivity assays could not detect the loss of response to artemisinins. However, a ring stage survival assay 63 , where early rings (forming within the first 3 h of erythrocyte invasion) from artemisinin refractory lines were exposed to 700 nM artemisinin for 6 h, showed they had enhanced ability to survive compared with sensitive lines. The same pheno type is found when various mutant alleles of Pfk13 are engineered into wild type parasites 64 . The function of Pfk13 is not known, although roles in protein ubiquitinylation have been predicted 65 . This includes ubiquitinylation of P. falciparum phosphati dylinositol 3kinase (PfPI3K), and increased phos phatidylinositol 3phosphate (PtdIns3P) levels have also been linked to diminished sensitivity to artemi sinins 66 . It was recently shown that parasites with Pfk13 mutant alleles have different kinetics of haemoglobin digestion 67 , which could also decrease the activation of the drug. Recently, a coronin encoding gene, which like Pfk13 encodes a member of the WD40propeller domain protein family, was identified in another P. falciparum line selected in vitro over a prolonged period for resistance to artemisinin 68 . Phenotypically, parasites with P. falciparum coronin gene mutant alleles mirror those of parasites with Pfk13 mutant alleles in that the ring stage survival assay is required to discrim inate sensitive and artemisinin refractory lines. The Pfk13 and P. falciparum coronin gene mutations are, therefore, somewhat analogous to the so called high persister (Hip) mutations that are known to enhance the rate at which persisters form in bacteria and yeasts 16 . Many of the known Hip genes are part of toxin-antitoxin protein pairs, and given the predicted capacity of Pfk13 to combine in protein complex formations 69 , it will be of interest to determine whether analogous functions can be found for Pfk13, P. falciparum coronin and any other proteins that confer enhanced dormancy and artemisinin refractoriness as they are identified.
Recent studies evaluated the ability of antimala rial drugs to prevent the recrudescence of artemisinin induced dormant ring stages. Mefloquine exposure reduced the rate of recrudescence but did not completely abrogate activation and growth 70 . However, PI4K inhib itors and imidazolopiperazines did block recrudescence of dormant ring forms of artemisinin susceptible and artemisinin resistant P. falciparum 71, 72 . A tetroxane based compound was shown to eliminate parasites carrying Pfk13 mutant alleles 73 probably because of its long elimination half life ensuring it remains at parasit icidal levels for more than 4 days and thus can kill drug induced dormant ring forms as they reactivate 73 . New data suggest that phytohormones 74 , including gibberellin and abscisic acid, activate DHA induced dormant rings 24-48 h earlier than controls treated with DHA alone and left to recover. This work offers a potential new route to drug discovery through reactivation of dormant forms, thereby resensitizing them to current drugs. Reactivation is a more viable strategy for tropical infectious diseases than seeking molecules that sustain the growth arrested state, as has been proposed for cancer cell persisters 11 , given economic considerations in long term provision of therapy for diseases that most commonly occur in underprivileged areas. An additional study demon strated the potential role of eukaryotic initiation factor 2α (eIF2α) phosphorylation as a mechanism promoting dormancy in ring stages in Plasmodium berghei 75 , which suggests that inhibition of eIF2α phosphorylation might prevent parasites entering dormancy 20 and thus retaining sensitivity to artemisinins. The role of eIF2α phospho rylation in controlling dormancy was initially described in sporozoites 76 , and the phosphorylation status of eIF2α has since been proposed as a key regulator of different dormancy in apicomplexans 20 .
Toxoplasma gondii
T. gondii, the causative agent of toxoplasmosis, is a tis sue cyst forming coccidian and a member of the phy lum Apicomplexa 77, 78 . The ability to generate dormant (or semidormant forms that grow slowly as opposed to being growth arrested) yet highly infective forms as part of the developmental life cycle is critical to the persistent nature of these parasites. T. gondii is one of the most widespread protozoan parasites infecting a diverse range of warm blooded vertebrate hosts, including humans 79 . Its complex, multihost developmental life cycle is defined by sexual and asexual stages, each with distinct yet related end forms that enable the parasite to persist in nature. The natural life cycle for T. gondii involves small rodents that serve as intermediate hosts and cats that serve as the definitive host 79 . Within enterocytes of the cat gut, the parasite undergoes sexual development, culminating in shedding of oocysts in the faeces 79 . After shedding, oocysts undergo meiosis to form eight haploid sporozoites, which remain dormant and do not divide, despite surviving in the environment for long periods 79 . Following oral infection, oocysts hatch, which enables sporozoites to invade the intestine and differentiate into replicating tachyzoites, which disseminate throughout the host, thus causing acute disease 79 . In response to immune pressure and environmental stress, the parasite 82 . Humans serve as inter mediate hosts and therefore the life cycle is similar to that described earlier for rodents. During the bradyzoite stage, infections are largely asymptomatic in immuno competent individuals, with disease arising when these infections reactivate in immunocompromised patients. Individuals undergoing chemotherapy or organ trans plantation or patients with untreated HIV are at risk of reactivation when bradyzoites emerge from tissue cysts and reconvert to rapidly growing tachyzoites, which resume lytic growth and destroy their host cells. The process of reactivation is particularly severe when tissue cysts harboured within the central nervous sys tem undergo reactivation 83, 84 . In the absence of appro priate antiparasitic treatment, the resulting syndrome of toxoplasmic encephalitis 85 can become life threatening. The tachyzoite tobradyzoite transformation con trols the transition between acute to chronic infection, while the reverse switch from semidormant bradyzoites to actively replicating tachyzoites is the key to disease reactivation. Gene expression analyses indicate that only a few hundred genes differ between tachyzoite and bradyzoite stages, whereas other stages (sporozoites and merozoites) show much greater differences 86 . However, the molecular basis of these life cycle transitions is not well defined. Slowing of the tachyzoite replication cycle 87 coincides with the expression of a bradyzoite specific transcriptional cascade [88] [89] [90] , which includes stage specific roles for apicomplexan AP2 transcription factors [91] [92] [93] [94] [95] that have also been implicated in transcrip tional regulation of development in Plasmodium spp.
Haemolytic anaemia
(that is, ookinete, sporozoite and gametocyte stages) [96] [97] [98] . These tightly regulated developmental responses enable parasites to balance dissemination within the host and chronic infection that allows host tohost transmission 99 . Studies have shown that stressors such as nutrient limi tation 100 , high pH 101 and nitric oxide exposure 102 can induce bradyzoite differentiation. Infection of long lived, differentiated cells such as skeletal muscle 103 and neurons 104 also induces bradyzoite formation and per sistent infections 105, 106 . Therefore, host immune pressure, environmental stressors and parasite specific genetic programmes can result in the formation of bradyzoite containing tissue cysts. Triggering differentiation back to actively growing tachyzoites is also not fully under stood, but might arise from abundance of nutrients or absence of immune pressure. Either model might explain why bradyzoites used to infect naive mice quickly revert to tachyzoite growth before later developing into new bradyzoites and forming tissue cysts 82 . This switching ability is not understood but it probably underlies the permissive nature of transmission between interme diate hosts, which include nearly all warm blooded animals, which are usually infected by ingestion of semi dormant tissue cysts 107 . This oral transmissibility of the asexual, tissue stages sets T. gondii apart from its close relatives that have more restricted modes of transmission.
Human infections arise either from ingestion of oocysts shed into the environment from the feline definitive host 108 or from consumption of undercooked meat contaminated with cyst bound bradyzoites 109 . Mothers first infected with T. gondii during pregnancy can transmit infection via tachyzoites crossing the pla cental barrier and infecting the fetus 110 . Although most infections are subclinical or result only in mild disease in healthy adults, hypervirulent strains of T. gondii in South America cause an increased incidence of ocular toxoplasmosis in immunocompetent patients 111 . Current therapies for toxoplasmosis based on pyrimethamine-sulfadiazine or trimethoprimsulfamethoxazole target DNA synthesis by inhibiting the folate pathway and are effective at blocking repli cation and killing tachyzoites 85 . Adverse reactions are common and include low tolerance due to bone marrow toxicity and allergy to sulfa components, while poten tial teratogenicity prevents use during the first trimester of pregnancy 85 . Clinical resistance to treatment (defined by the emergence of mutations rendering parasites sta bly insensitive to a drug) is rare as human infections are zoonotic (and food animals are not routinely treated for toxoplasmosis) and human tohuman transmission is uncommon.
Although current therapies can control acute infec tion, owing to their mode of action, chronic infections are unaffected. Replicating tachyzoites are vulnerable, but slowly or asynchronously replicating bradyzoites are not 85 (Fig. 2) . Typically, bradyzoite numbers expand as they replicate, so tissue cysts contain 100-500 indi vidual parasites over the course of 1-2 months (sug gesting an average doubling time of several days), whereas tachyzoites double in number every 6-8 h (reF.
80
). Although pyrimethamine eliminates tachyzoites in culture overnight, a 4h exposure followed by drug wash out does not inhibit parasite replication, and www.nature.com/nrmicro hence continuous exposure of replicating tachyzoites over prolonged periods is required for effective treat ment 112 . Neither the blood-brain barrier 85, 113 nor the heavily glycosylated tissue cyst wall 114, 115 is a physical barrier to pyrimethamine, which suggests that the semi dormant state of the bradyzoite is responsible for treat ment failure. Alternative treatments such as clindamycin (which inhibits protein synthesis in the vital apicoplast organelle) also target actively replicating forms 85 . New drugs to treat toxoplasmosis are actively being investigated. The Malaria Box and Pathogen Box com pounds selected in high throughput screens against P. falciparum and other pathogens were screened to find compounds that hit biological targets shared among apicomplexans 116 . A number of other chemical libraries have been tested against T. gondii to possibly identify new therapeutic compounds [117] [118] [119] [120] , including all FDA approved drugs, seeking compounds for repurposing. In addition, screening of compounds that are active against malaria identified relatively few candidates that were effective against T. gondii 121 . Atovaquone 122 and ELQ300 (reF.
123
) are effective against tachyzoites and both compounds reduced tissue cyst numbers in chroni cally infected mice but complete cure was not achieved. Intriguingly, primaquine, used to treat patients with P. vivax hypnozoites, has modest activity against T. gondii tachyzoites, but its therapeutic use against the bradyzoite has not been evaluated 124 . In separate studies, inhibi tors of calcium dependent protein kinase 1 (CDPK1), an essential enzyme in T. gondii, have shown promise for eradicating infection in immunocompromised mice 112 . Learning more about essential processes in bradyzoites may lead to therapies that control or eliminate this stage.
Trypanosoma cruzi T. cruzi, which causes Chagas disease, afflicts millions of people, mostly in Latin America
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, and is vectored by blood feeding insects of the Triatominae subfamily of reduviid bugs. Infections in humans and in many other mammals are often low level but lifelong and generally immune controlled. The preferential persistence of T. cruzi in muscle, and the continued immune response to parasites in heart and other muscle tissues, probably accounts for the cardiac and gut pathology associated with Chagas disease. Infection with T. cruzi generally begins with invasion by flagellated (non replicative) trypomastigotes transmitted in bug faeces as they feed on their hosts. Trypomastigotes enter host cells and dif ferentiate into amastigotes, which divide, notably in the host cell cytoplasm and not in a vacuole, by binary fis sion. Amastigotes reconvert to trypomastigotes, which are released from the lysed host cell and invade new cells or are available in the blood for transmission. The intracellular replication cycle generally lasts for 4-5 days, although it can be slower for some isolates 126 .
T. cruzi amastigotes are the primary targets of both immune control and drug treatment. Benznidazole and nifurtimox have rapid trypanocidal activity against T. cruzi and have been used therapeutically for dec ades. However, long treatment courses (30-60 days) are required and outcomes are unpredictable. These and other observations prompted the suggestion of drug insensitive and potentially dormant subpopulations of T. cruzi in hosts 127 .
Dormant amastigote forms of T. cruzi.
Recently, non replicating intracellular T. cruzi amastigotes were demonstrated in both mice and cultured host cells 17 . These dormant parasites occur spontaneously in the absence of drug pressure but resist killing by multiple trypanotoxic compounds that are highly active against replicating parasites. Entering the quiescent state seems not to be a response to a lack of nutrients or to the presence of other obvious stressors, as non replicating amastigotes are frequently present in host cells along side actively dividing amastigotes. Furthermore, these non replicating amastigotes sense the signals that trig ger amastigote totrypomastigote differentiation, as they differentiate synchronously with the actively dividing forms in the same host cell (Fig. 3) . Trypomastigotes derived from non replicating amastigotes can invade new host cells and re establish both actively dividing and non dividing progeny, a hallmark of phenotypic heterogeneity in bacterial persisters. Formerly dormant amastigotes emerging after a 30day continuous drug exposure in vitro are equally sensitive to the drug as the parent (untreated) population 17 , and hence drug expo sure has not selected for genetically resistant parasites, instead suggesting that dormancy is the cause of drug refractoriness. Transient dormancy (that is, dormant cells that will reactivate) among a small subpopulation of intracellular T. cruzi amastigotes therefore underlies NATuRe Reviews | MiCRObiOlOGy treatment failure of anti T. cruzi compounds that kill actively dividing amastigotes. Although the metabolic state of non replicating amastigotes has yet to be probed, dormant amastigotes have lower levels of expression of reporter proteins, which suggests decreased protein synthetic capacity and altered metabolism 17 . Many questions remain concerning dormancy in T. cruzi. Dormant amastigotes are not actively trans mitted; instead trypomastigotes must reach the host bloodstream to be taken up by blood feeding vectors. So what is the selective advantage of dormancy? Immune detection and control of T. cruzi is generally highly effec tive in keeping parasite load low. Host cells containing only dormant amastigotes probably evade surveillance by CD8 + T cells or other immune effectors and thus could function as reservoirs for the low but continuous production of trypomastigotes. This could extend the timeframe over which transmission is possible and con tribute to parasite persistence by reseeding tissue sites with new persister like parasites. The occasional reacti vation of these dormant parasites might also account for the dynamic nature of T. cruzi infection (for example, the appearance of new sites of parasite replication, appearing and disappearing in different anatomical locations) 128 . Hosts with shorter T. cruzi infections (for example, children) may be more responsive to drug treatment than those with longer infections (decades in humans); of note, this conclusion is still debated and is complicated by how cure is determined [129] [130] [131] . If true, longer infections could result in increased seeding of tissues with dormant parasites, some of which may have exceptional longevity in the dormant state and thus avoid clearance by current, time limited, treatment protocols.
As T. cruzi rarely undergoes sexual recombination, instead recombining and resorting existing genes to generate genetic and antigenic diversity 132 , dormant amastigotes might function as a stable 'stem like' cell should the gene resorting yield compromised progeny in replicating forms.
It seems that the length of time that amastigotes stay dormant, or at least for the ability of an infection to persist under drug pressure, is finite. Sterile cure with drugs can be achieved, in some cases, with treatment courses as short as 10-20 days 133, 134 and some, albeit not all, in vitro cultures clear parasites following a 30day drug exposure 17 . For some T. cruzi strains, 16 days of in vitro exposure to benznidazole is sufficient to steri lize the culture 135 . However, 30day and even 60day treat ment regimens in humans and other animals often fail, and dormancy in combination with other features of the infection (for example, the establishment of infection in a wide range of tissues which differ in drug penetration) is likely to be responsible. On the basis of this, currently available drugs might be more efficacious if used over longer periods (for example, several months), possibly at lower frequency of dosing to keep the overall dose down. Indeed pulse treating with benzni dazole once every 5 days 136 or even once every 7 days (J. Bustamante, unpublished observations) over several months can be as or even more efficacious than shorter, daily treatment protocols.
New trypanocidal compounds that can target dormant forms are clearly desirable. Nifurtimox and benznidazole both require metabolic activation by trypano somal enzymes 137 , the activity of which is likely to be reduced in dormant forms. Therefore, establishing screens specific for these dormant forms may identify a new generation of drugs. The observation that non dividing amastigotes can respond to the cues that trigger stage conversion to trypomastigotes also offers the possi bility of finding molecules that might activate dormant parasites and sensitize parasites to existing drugs.
Leishmania species
The leishmaniases represent a series of conditions caused by more than 20 different species of the genus Leishmania 138 that belong to the same phylogenetic order, the Kinetoplastida, as African and American trypanosomes. Leishmaniases span self healing cuta neous disease to a frequently fatal visceral form. Around one million clinical cases are reported each year, with ~10fold that number of people having subclinical infections in nearly 100 countries in the tropics and . The parasites are transmitted by sandflies (Fig. 4) . In the sandfly, a series of different flagellated promastigote forms complete the life cycle, culminating in the formation of growth arrested metacyclic pro mastigotes in the mouth parts ready for transmission to the vertebrate host. There they enter phagocytes, where they transform into amastigote forms within the phagolysosome to establish infection.
Successful treatment of leishmaniasis is notoriously difficult. Pentavalent antimony formulations were the mainstay of treatment for many years 139 but toxi city and parasite drug resistance increasingly limit use. Milte fosine and paromomycin are used in some set tings 139 . Amphotericin B, which binds to ergosterol found in both fungal and leishmanial membranes but not mammals, has become the drug of choice in many countries (its lipo somal formulation, AmBisome, being safer than the non encapsulated drug 140 . For cutaneous leishmaniasis, a posttreatment relapsing form is known as leishma niasis recidivans 141 . Both conditions are likely to arise from persister type parasites; that is, parasites that have survived drug treat ment due to transient drug refractoriness during dor mancy. They reawaken into an immuno logically altered environment as the immune system has responded to the primary infection, and in currently ill understood ways, they re establish a pathological condition in the skin. Drug resistance mecha nisms have been discov ered 142 , and it is clear that drug treatment failure due to stably transmitted genetic mutation is an increasing problem. For example, treatment failure with antimony formulations in the Indian subcontinent has been traced to mutated aquaporin 1 (which is encoded by the AQP1 gene), which transports antimony into the cells 143 . A genetic locus associated with milte fosine resistance in field isolates has been identified 144 , and changes in genes involved in sterol metabolism have been implicated in amphotericin B resistance 145, 146 . However, treatment fail ures without classic genetic based heritable resistance are also widespread (for example, PKDL and leishma niasis recidivans), which indicates that Leishmania spp., like T. cruzi, produce persister like cells.
Dormant forms of Leishmania species.
In mammals, Leishmania spp. dwell primarily within macrophages and dendritic cells. The growth rate of Leishmania mexi cana in non resolving infections in Balb/c mice 147 was determined to be slow but constant, doubling every 12 days, and it was concluded that amastigotes are sem iquiescent in mice. Moreover, in mice, amastigotes (as an overall population) were shown to have a stringent metabolism, consuming relatively sparing quantities of metabolites as a source for carbon and energy and using them relatively efficiently compared with the cul tured promastigote form 148 . The possibility of dividing and non dividing subpopulations was not taken into account in that study. However, discrete replicating and non dividing intracellular amastigote populations were discriminated in a C57BL/6J mouse model of L. major cutaneous disease 18 . Four months after infection, two distinct populations could be distinguished on the basis of their ability to incorporate the nucleotide analogue 5bromo2′deoxyuridine into DNA: one actively divid ing population that doubled around every 60 h and a non dividing, dormant population. In the early days following infection, amastigotes divide at a similar rate (around every 60 h) but fewer dormant forms are found. Learning more about the comparative phenotypes of dormant and replicating Leishmania spp. amastigotes will shed more light on these persister like cells.
Other Leishmania species also exhibit potential persister like cellular states. Comparison of L. (Viannia) braziliensis promastigotes and amastigotes 149 showed that amastigotes have diminished levels of protein, RNA, mitochondrial kinetoplast DNA and ATP and exhibit no growth in macrophages in vitro. Untargeted metabolomics showed that axenic amastigotes also had diminished levels of multiple amino acids and poly amine pathway metabolites compared with promasti gotes. Metabolomics offer a key route to understanding the persister phenotype (box 1).
Ergosterol
Major sterol of the Leishmania plasma membrane, also found in fungi. binds to amphotericin b.
Box 1 | Methods to study protozoan persister-like cells
Fluorescent probes
Fluorescent probes have become essential to visualize dormant protozoan cells. labelling parasites using classic fluorescent reporters such as GFP, DsRed or Tmtomato are used to identify the parasites themselves. labels that enter cells on a pulsed exposure and are then either diluted out during cell division or remain at their initial pulse level in non-replicating cells allow differentiation between replicating and nonreplicating cells. CellTrace violet, carboxyfluorescein succinimidyl ester and CellTracker Red are examples of dyes used for this purpose. Fluorescence-activated cell sorters can be used to sort differentially labelled populations for further analysis.
DNA replication probes
Non-replicating cells do not incorporate new bases into their DNA, while replicating cells do. The thymidine analogues 5-ethynyl-2′-deoxyuridine and 5-bromo-2′-deoxyuridine have both been shown to be effectively incorporated into replicating DNA of Leishmania spp. and Trypanosoma cruzi, whereas non-replicating cells did not incorporate the activated derivatives of these analogues. To visualize their incorporation it is necessary to fix cells and use specific antibodies to detect them, precluding their use in sorting live cells. Toxoplasma gondii 155 and Plasmodium spp. 156 do not salvage thymidine and hence can be labelled only with 5-bromo-2′-deoxyuridine and similar probes after stable transfection of thymidine kinase.
Sorting quiescent and replicating cells
Cells that have been labelled with fluorescent dyes (see above) can be separated using fluorescence-activated cell sorters. This approach can also be used to sort cells in which fluorescent reporters (for example, GFP) are regulated by stage-specific promoters, for example to separate tachyzoites from bradyzoites of T. gondii. Another simple method for enrichment of persister-like cells is to treat a mixed population with varying doses of antimicrobials that kill replicating cells but not quiescent cells followed by the analysis of the viable cells remaining after treatment.
Metabolomics untargeted metabolomics analysis allows the comprehensive profiling of metabolite levels in different cell types. As persister-like cells have altered metabolism when compared with proliferative cells, but genome sequences are unchanged, metabolomics offers a key route to profile the differences in biochemical physiology that distinguish cell types.
Transcriptomics and proteomics
Also relating to the fact that the genomes of persister-like cells are unaltered, profiling the transcriptome and proteome of different cell types can report on adaptations to the quiescent cell phenotype and point to metabolic pathways that might be targeted in these cells.
Single cell transcriptomics
Profiling transcription in single cells, rather than population averages, will allow a more detailed understanding of the changes at the transcriptional level that could be linked to the formation of persister-like cells.
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Non replicating L. donovani was also found in in vitro cultivated THP1 macrophages 150 , prompting speculation that these too represent persister like cells. Although in their infancy, studies of these growth arrested leishmania forms will probably provide answers to the frequent drug treatment failures in the absence of genetically selected resistant parasites 151 . Studying persister cells in vivo is challenging owing to low abundance and inaccessibility, their being dis tributed across multiple host organs (box 1). As an evolutionarily ancient trait 8 , rather than an adapta tion to mammalian parasitism, other life cycle stages of Leishmania spp. might be expected to form quies cent forms to allow population level survival during environmental stresses. Non replicative forms also have important roles in the life cycle; for example, the transmitted metacyclic form is analogous to the non proliferative Plasmodium spp. sporozoite. L. donovani promastigotes enter a non proliferative but viable qui escent state in purine depleted culture conditions 152 . Proteomics analysis 153 revealed that purine transporters and purine salvage enzymes were upregulated within 24 h of purine deprivation (presumably in an attempt to restore purine levels). However, after 48 h, a profound remodelling of the proteome had occurred: the levels of enzymes involved in DNA replication and repair and in protein synthesis were diminished, while proteins associated with some oxidative stress response path ways were increased, all hallmarks of persister like cells. In bacteria 7 and fungi 10 too, nutrient starvation responses have considerable overlap mechanistically with the for mation of persister cells, and hence the leishmanial pro mastigote model may offer a tractable means of probing mechanisms of persister like cell formation and guide studies in less readily studied amastigotes (box 1).
Very recently insertion of a GFP gene into the ribo somal gene locus of both L. mexicana and L. braziliensis was reported in a preliminary study 154 . Transfor mation of promastigotes to amastigotes in both species led to pronounced reduction in expression of the reporter gene, consistent with decreased translation in amastigotes. 5Bromo2′deoxyuridine labelling showed that parasites with low GFP expression levels were also non replicative. Axenic amastigotes were shown to form two populations (bright and dull with respect to GFP expression, and were presumed to represent proliferative and non replicating cells, respectively). All macrophage resident amastigotes had dull expression. With use of CellTracker Deep Red staining, in vivo, parasites retaining the dye (and thus not replicating) could be found up to 120 days after infection. GFP fluorescent parasites at this time lacked the dye, indicating that this dual staining approach can distin guish non proliferating (CellTracker positive) and pro liferating (GFP positive, CellTracker negative) parasites. The toolkit necessary to probe Leishmania persisters more deeply is thus emerging.
To date, testing the susceptibility to drugs of dormant Leishmania spp. amastigotes has not been performed. However, by analogy to other systems -and given the widespread nature of drug treatment failure (including PKDL and leishmaniasis recidivans) -it is probable that these parasite forms are refractory to treatment with antileishmanial drugs, and by learning more about their biology, we will be able to improve therapeutic interventions.
Concluding comments
Persister populations are increasingly appreciated as a problem leading to drug treatment failure in bacteria, fungi and cancer cells. Many parasitic protozoa also display the dormant/quiescent properties characteristic of persister phenotypes, ranging from discrete life cycle stages (for example, non dividing P. vivax hypno zoites and slow growing T. gondii bradyzoites) to the stochas tically arising, non dividing amastigotes of T. cruzi to the slow growing and non replicating amastigotes of Leishmania spp. As in bacteria, these protozoan persister like cells exhibit drug tolerance and are likely to be responsible for frequent drug treatment failure. Besides some advances, many challenges remain in studying protozoan persister like cells: these cells are generally of low abundance in mammalian hosts and are either non replicating or only slowly growing; their tissue distribution is not well defined in mammalian hosts and they can be difficult to find; and in vitro methods for their cultivation are not well developed Understanding the mechanisms of dormancy, which involves reversible metabolic changes (Fig. 5) , might lead to new treatment strategies. For example, screens that specifically target persister cells may lead to the discovery of compounds that facilitate sterile cure, either alone or together with current compounds that eliminate actively In addition, in purine-depleted culture conditions, Leishmania donovani non-proliferative promastigotes exhibit decreased DNA replication and repair and protein synthesis, whereas proteins associated with some oxidative stress response pathways are increased. Finally, in apicomplexan protozoa, phosphorylation of parasite eukaryotic initiation factor 2α (eIF2α) has been implicated in the establishment of dormancy (possibly by inhibiting global protein synthesis), although the role of role eIF2α phosphorylation in the formation of persister-like cells in kinetoplastid protozoa has yet to be investigated. ROS, reactive oxygen species.
replicating cells. It may also be possible to use current drugs in different ways; for example, pulsing therapy at intervals that mean reactivated persisters that emerge are confronted with a drug to which they are sensitive. Alternatively, small molecules that trigger reactivation could resensitize the parasites to currently used drugs.
Finally, the identification of small molecules that modulate dormancy will also provide new tools for understanding the molecular basis of persister phenotypes.
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